Genentech
Genentech, a member of the Roche Group, is a pioneering biotechnology company headquartered in South San Francisco, US. Founded in 1976, Genentech has been at the forefront of the biotechnology industry, focusing on the development of innovative medicines for serious medical conditions. The company is renowned for its contributions to oncology, immunology, and neuroscience, with a portfolio that includes groundbreaking therapies such as Herceptin and Avastin. With a commitment to research and development, Genentech has achieved numerous milestones, including the first-ever recombinant DNA product approved by the FDA. Its unique approach to drug development, combining cutting-edge science with a patient-centric philosophy, has solidified its position as a leader in the biopharmaceutical market. Genentech continues to set benchmarks in the industry, driving advancements that improve patient outcomes globally.
DitchCarbon Score
How does Genentech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genentech's score of 40 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genentech's reported carbon emissions
In 2019, Genentech reported total carbon emissions of approximately 140,550,000 kg CO2e, which includes Scope 1 emissions from stationary combustion (61,780,000 kg CO2e) and fugitive emissions (3,242,000 kg CO2e), as well as Scope 2 emissions from purchased electricity (36,718,000 kg CO2e) and Scope 3 emissions from business travel (55,446,000 kg CO2e) and employee commute (18,154,000 kg CO2e). Genentech has not disclosed specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests a need for further clarity on their long-term sustainability goals. The company operates within the pharmaceutical industry, which is increasingly focusing on reducing carbon footprints and enhancing sustainability practices. Overall, while Genentech has made strides in tracking emissions across various scopes, the lack of defined reduction targets indicates an opportunity for the company to strengthen its climate commitments moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2004 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 2,022,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 54,533,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 21,308,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genentech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
